POLYVALENT PNEUMOCOCCAL VACCINES Russian patent published in 2024 - IPC A61K38/16 C07K14/315 

FIELD: biotechnology.

SUBSTANCE: described is a polyvalent vaccine containing fifteen or more types of immunogenic complexes. Each of the types of immunogenic complexes contains: (a) a biotinylated polysaccharide antigen containing biotin and a polysaccharide antigen from a single serotype Streptococcus pneumoniae; and (b) a fused protein. Fusion protein comprises: (i) a biotin-binding fragment; (ii) a first polypeptide antigen comprising an SP1500 polypeptide or an antigenic fragment thereof; and (iii) a second polypeptide antigen comprising the SP0785 polypeptide or an antigenic fragment thereof. In each of the types of immunogenic complexes, the biotinylated polysaccharide antigen is non-covalently bound to the biotin-binding fragment of the fused protein. Vaccine is characterized by the fact that after administration to a subject, it induces an immune response against Streptococcus pneumoniae. Also described is a pharmaceutical composition containing said polyvalent vaccine and a pharmaceutically acceptable carrier. Pharmaceutical composition is characterized by the fact that after administration to a subject, it induces an immune response against Streptococcus pneumoniae. Disclosed is a method of producing a polyvalent vaccine. Method involves mixing fifteen or more types of immunogenic complexes in one composition. Each type of immunogenic complexes includes: (a) a biotinylated polysaccharide antigen containing biotin and a polysaccharide antigen from a separate serotype Streptococcus pneumoniae; and (b) a fused protein. Fusion protein comprises: (i) a biotin-binding moiety; and (ii) a first polypeptide antigen comprising an SP1500 polypeptide or an antigenic fragment thereof; and (iii) a second polypeptide antigen comprising the SP0785 polypeptide or an antigenic fragment thereof. In each of the types of immunogenic complexes, the biotinylated polysaccharide antigen is non-covalently bound to the biotin-binding fragment of the fused protein, and the vaccine is characterized by the fact that after administration to a subject, it induces an immune response against Streptococcus pneumoniae. Also disclosed is a method of immunizing a subject against Streptococcus pneumoniae infection and/or colonization, comprising administering to the subject an immunologically effective amount of a polyvalent vaccine or a pharmaceutical composition.

EFFECT: invention extends the range of agents for controlling Streptococcus pneumoniae.

16 cl, 26 dwg, 6 tbl, 11 ex